Alpha 2.0
Login Register
» Authors » Akihito Tsuji

Akihito Tsuji

Explore the profile of Akihito Tsuji including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 142
Citations 3960
Followers 0
Related Specialties
Oncology
Gastroenterology
General Medicine
Top 10 Co-Authors
Hisateru Yasui
Tomohiro Nishina
Masahito Kotaka
Eiji Oki
Hironaga Satake
Takayuki Yoshino
Kentaro Yamazaki
Tadamichi Denda
Takeshi Kato
Kei Muro
Published In
Int J Clin Oncol
Cancer Chemother Pharmacol
Gan To Kagaku Ryoho
Gastric Cancer
BMC Cancer
Affiliations
Soon will be listed here.
Recent Articles
11.
Novel endoscopic duodenal observation protocol based on Seven Pictures Rule for detecting duodenal neoplasms during esophagogastroduodenoscopy: Prospective observational study
Kozuka K, Kobara H, Matsui T, Fujisawa A, Tatsuta M, Kobayashi M, et al.
Dig Endosc . 2023 May; 36(2):154-161. PMID: 37171696
Objectives: No protocol for esophagogastroduodenoscopic examination of the duodenum has been established. We examined the feasibility and ability to detect neoplasms of a novel duodenal examination protocol. Methods: This was...
12.
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, et al.
Target Oncol . 2023 Apr; 18(3):359-368. PMID: 37060430
Background: This study investigated whether schedule modification of bi-weekly nanoparticle albumin-bound paclitaxel (nab-PTX) plus ramucirumab (RAM) is efficacious against gastric cancer (GC) or gastroesophageal junction cancer (GJC). Patients And Methods:...
13.
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program
Nakamura Y, Yamashita R, Okamoto W, Komatsu Y, Yuki S, Ueno M, et al.
JCO Precis Oncol . 2023 Mar; 7:e2200653. PMID: 36996376
Purpose: Genomic profiling programs have been implemented to apply next-generation sequencing (NGS) for facilitating trial enrollment. SCRUM-Japan GI-SCREEN is a large-scale genomic profiling program in advanced gastrointestinal cancers using a...
14.
Income Change One Year after Confirmed Cancer Diagnosis and Its Associated Factors in Japanese Patients
Murakami A, Kanda K, Ngatu N, Chujo K, Yamadori Y, Mashima Y, et al.
Int J Environ Res Public Health . 2022 Dec; 19(23). PMID: 36498064
The number of patients who survive for a long time after cancer diagnosis is rapidly increasing; however, such patients experience major problems such as returning to work and changes in...
15.
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the...
Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, et al.
Int J Clin Oncol . 2022 Jul; 27(9):1450-1458. PMID: 35861943
Background: Primary tumor location is considered a predictor of overall survival (OS) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) treated with bevacizumab (BEV) or an anti-epidermal growth factor antibody...
16.
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, et al.
BMC Cancer . 2022 Jun; 22(1):711. PMID: 35765021
Purpose: Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic...
17.
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, et al.
Esophagus . 2022 Jun; 19(4):683-692. PMID: 35668304
Background: The phase 3 KEYNOTE-590 (NCT03189719) study showed first-line pembrolizumab plus chemotherapy significantly prolonged overall survival and progression-free survival versus placebo plus chemotherapy in patients with advanced unresectable or metastatic...
18.
Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer
Suto H, Okano K, Oshima M, Ando Y, Matsukawa H, Takahashi S, et al.
Pancreas . 2022 May; 51(3):269-277. PMID: 35584385
Objectives: Indications of preoperative treatment for resectable (R-) or borderline resectable (BR-) pancreatic ductal adenocarcinoma (PDAC) are unclear, and the protocol remains to be standardized. Methods: Included 65 patients with...
19.
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, et al.
JCO Precis Oncol . 2022 May; 6:e2100535. PMID: 35544728
Purpose: Low concordance between plasma-based and tissue-based tests for determining the mutational status have been reported in some but not all patients with limited-extent metastatic colorectal cancer (mCRC). In this...
20.
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
Tanioka H, Shimada K, Tsuji A, Kochi M, Kim H, Takahashi T, et al.
Anticancer Res . 2022 Apr; 42(5):2675-2681. PMID: 35489740
Background/aim: The usefulness of angiogenesis inhibitors as second-line treatment after the progression of anti-epidermal growth factor receptor antibody drug-containing regimens for RAS wild-type metastatic colorectal cancer (mCRC) has not been...